On July 7, Eli Lilly rose 3.36% in regular trading, reaching $1,235.14/share and hitting a fresh all-time high, with total market capitalization surpassing $1.18 trillion. The rally was driven by multiple investment bank upgrades and a key regulatory approval for its blockbuster diabetes drug.

JPMorgan raised its price target on Eli Lilly from $1,300 to $1,400, implying approximately 17% upside from current levels. Analyst Chris Schott projected quarterly revenue of $20.7 billion and EPS of $8.85, both above consensus, citing continued international expansion of Mounjaro and robust U.S. obesity market growth. Cantor Fitzgerald also lifted its target from $1,230 to $1,350.

Separately, Health Canada officially approved Mounjaro (tirzepatide) for treatment of type 2 diabetes in patients aged 10 and older, further broadening the drug's addressable patient population. The broader pharmaceutical sector traded higher, with Johnson & Johnson up 3.2%, Pfizer up 1.54%, and Novo Nordisk up 1.42%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)